Background/Aims: IGF2BP2 has been reported to serve as an oncogene in various solid cancers. However, the role of IGF2BP2 in acute myelocytic leukemia (AML) is still unknown. Methods: Public databases Gene Omnibus was used to evaluate the expression of IGF2BP2 in AML patients and healthy controls. In addition, primary cells from these two populations were prepared by Ficoll density centrifugation. Rt-qPCR and western blot were used to detect IGF2BP2 expression in the primary cells from these two populations. Meta-analysis was performed to evaluate the association of IGF2BP2 and prognosis. Lentivirus-based shRNAs were used to knock down IGF2BP2 in AML cell lines KG-1a and Kasumi. Results: We searched the public database Gene Omnibus and analyzed IGF2BP2 expression in both AML and healthy populations. The results showed that IGF2BP2 was overexpressed in AML patients. To verify this phenomenon in fresh human samples, we compared the expression of IGF2BP2 in primary cells from 10 AML patients and 10 healthy controls and found that the expression of IGF2BP2 was upregulated in AML primary cells. More importantly, we observed that IGF2BP2 expression was negatively correlated with the CEBPA mutation status, which is an indicator of good prognosis (RR=0.648, p=0.0001). In addition, IGF2BP2 expression was positively associated with poor prognostic factors, such as the FLT3-ITD mutation (RR=1.198, p=0.0009) and IDH1 mutation (RR=1.354, p=0.0003), as well as intermediate and poor cytogenetic risk (RR=1.214, p=0.0026). To evaluate the prognostic value of IGF2BP2 in AML, we further performed a meta-analysis of 8 studies consisting of 1731 patients and found that IGF2BP2
IGF2BP2 Overexpression Indicates Poor Survival in Patients with Acute Myelocytic Leukemia
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Introduction
Acute myelocytic leukemia (AML) is a common malignant disease of the hematopoietic system [1, 2] . According to statistics reported by the American Cancer Society in 2016, approximately 19, 950 new cases and 10, 430 deaths from AML are expected in the United States [3] . AML is characterized by high heterogeneity, and its prognosis varies greatly. Mutations in CEBPA, NPM1, FLT3, MLL, IDH1 or IDH2, DNMT3A, and ASXL1 have been suggested to predict the outcome of patients with AML [4, 5] . However, these biomarkers are based on the gene mutations of patients. It is necessary to identify new biomarkers to predict the prognosis of AML and develop personalized treatments.
IGF2 mRNA binding protein 2 (IGF2BP2) is an RNA-binding protein that plays an important role in regulating the differentiation potentials of mouse neocortical neural precursor cells as well as myoblast proliferation, myogenesis, muscle cell motility and energy metabolism [6] [7] [8] . IGF2BP2 has been recently reported to be overexpressed in several types of solid cancers [9, 10] . IGF2BP2 overexpression promotes glioblastoma multiforme (GBM) progression by activating the IGF2/PI3K/Akt pathway and makes GBM resistant to temozolomide treatment [11] . In addition, IGF2BP2 promotes hepatocarcinogenesis by inducing inflammation [12] . Moreover, elevated IGF2BP2 is associated with poor survival in esophageal adenocarcinoma and basal-like breast cancer patients [9, 10] . Therefore, IGF2BP2 is a potential oncogene and prognostic marker in solid cancers. However, the role of IGF2BP2 in AML has not yet been investigated.
In this study, we first investigated the role of IGF2BP2 expression in AML by in silico analysis and tested its prognostic significance. By searching public datasets, we found that IGF2BP2 is upregulated in AML patients and significantly associated with poor overall survival in AML patients. In addition, IGF2BP2 knockdown significantly inhibits the growth of AML cell lines. Thus, IGF2BP2 could serve as a potential prognostic marker and promising therapeutic target in AML patients.
Materials and Methods

Primary cells from healthy controls and AML patients
Ten healthy controls and ten AML patients were included in this study, and informed consent was obtained from all participants. Primary mononuclear cells were collected from the bone marrow samples of healthy controls and AML patients by Ficoll density centrifugation. To better represent the characteristics of AML, the leukemia blasts from AML patients had an 85% or higher purity.
Quantitative Real-time Polymerase Chain Reaction (qRT-PCR)
RNA was isolated from primary patients with AML and healthy controls according to the protocol of an RNeasy Mini Kit (Qiagen #74104) and was then used to synthesize cDNA by using a PrimeScript™ RT Reagent Kit with a gDNA Eraser (TaKaRa #RR047A). qRT-PCR was performed with a SYBR® Green Real-time PCR Master Mix kit (TOYOBO #QRT-201). The reaction volume of the qRT-PCR reactions was 20 μl, containing forward and reverse primers (0.4 μM), 2 μl template DNA, 10 μl SYBR® Green Real-time PCR Master Mix and 6.4 μl PCR-grade water. qRT-PCR was performed on a Roche LightCycler™, and the cycling conditions were as follows: 95°C for 30 sec, followed by 40 cycles at 95°C for 5 sec, 60°C for 10 sec and 72°C for 15 sec. GAPDH was used as the housekeeping gene. Amplification efficiencies for IGF2BP2 and GAPDH primer 
Western blotting
In brief, cellular proteins were extracted from the primary cells or cell lines and separated by SDS-PAGE. The proteins in the gel were then transferred onto polyvinylidene fluoride (PVDF) membranes (Bio-Rad, Hercules, CA). The membranes were blocked in 5% BSA/TBST for 1 hour and then washed with TBST and incubated with a primary rabbit anti-IGF2BP2 antibody (Abcam ab124930) and primary rabbit anti-GAPDH antibody (Abcam ab181602) at 4°C overnight. The membranes were then washed with TBST and incubated with a secondary goat anti-rabbit IgG antibody (Abcam ab6721). Finally, the membranes were washed with TBST, and the protein expression levels were detected by chemiluminescence (Thermo ScientificTM #32104).
Knockdown of IGF2BP2
Lentivirus-based shRNAs targeting IGF2BP2 (NM_001007225) were purchased from GeneChem (28870-28873, Shanghai, China). The targeting coding sequences of IGF2BP2 were as follows: IGF2BP2 shRNA1, 5'-TAACCAGTGCAGAAGTCAT-3'; IGF2BP2 shRNA2, 5'-GATCTTTGGGAAACTGAAA-3'; IGF2BP2 shRNA3, 5'-GTGCTGAGATAGAGATTAT-3'; IGF2BP2 shRNA4, 5'-ATATACAACCCGGAAAGAA-3'. Lentivirus transduction was performed according to previously described methods [14] . Briefly, 2 ml of virus was added to the cells containing 5 μg/ml protamine sulfate, followed by overnight coculture. The cells were centrifuged and washed with PBS and then cultured in fresh medium with 2 µg/ml puromycin for three days. The cells were then collected to detect the mRNA and protein expression of IGF2BP2.
Cell proliferation assay
The AML cell lines KG-1a and Kasumi were purchased from the American Type Culture Collection (ATCC) and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY). A total of 2×10 3 KG-1a and Kasumi cells were seeded in 96-well plates and cultured at 37°C. The cells were divided into five groups, including one shControl group and four shRNA groups. Each group had five replicates. Cell proliferation was determined by CCK-8 assays (Dojindo Lot.JE603) at various time points according to the methods of the manufacturer.
Gene Omnibus (GEO) dataset analysis GEO datasets (GSE13159, GSE7186, GSE48558) were downloaded, and the normalized data were used to analyze the differential expression of IGF2BP2 in AML patients and healthy controls. The GEO dataset (GSE6891) containing 521 AML cases was chosen to test the relationship between IGF2BP2 expression and the clinicopathological features. Normalized and processed data from the RNA-seq sequencing GEO dataset (GSE80946) were analyzed to acquire the differentially expressed genes between the shRNA-targeting IGF2BP2 group and the shRNA control group. For the sets of differentially expressed genes, the enriched Gene Ontology terms were identified by using the DAVID program [15, 16] . Gene set enrichment analysis (GSEA) was also performed by using GSEA v2.0 software, which was available from the Broad Institute (http://www.broad.mit.edu/gsea) [17] .
Survival analysis and meta-analysis
The survival analysis was based on the expression data of IGF2BP2 from various GEO datasets (GSE12417, GSE8043, GSE10358, GSE1427, GSE6891), and the clinical survival information was obtained from PREdiction of Clinical Outcomes from Genomic profiles (PRECOG) or provided by the author [19] [20] [21] [22] [23] [24] [25] 32] . After collecting the survival information and IGF2BP2 expression values, hazard ratio (HR) values were recalculated or obtained directly from PRECOG to perform the survival analysis. The median expression value was selected to define the cut-off value for high IGF2BP2 expression.
A meta-analysis was conducted to evaluate the overall association between IGF2BP2 expression and survival in patients with AML. The pooled HRs and their 95% CIs were used in this meta-analysis. An observed HR value>1 indicated that high IGF2BP2 expression was correlated with poor survival in AML patients. If the 95% CI value did not overlap with a value of 1, the results were considered statistically significant. A heterogeneity analysis was carried out based on the Chi-square-based Q statistical test, and a P value>0.1 implied no heterogeneity across the studies [33] . In such cases, a fixed-effect model (the Mantel-Haenszel method) was used to perform the meta-analysis instead of a random-effect model (the DerSimonian and Laird method) [33, 34] . Both Egger's test and Begg's test were adopted to calculate the publication bias, and a p value< 0.05 indicated that bias existed.
Statistical analysis
Differential gene expression and a heat map analysis were carried out by using R software and GeneSpring GX. The statistical analyses of the meta-analysis were performed using STATA version 12.0 software (Stata Corporation, Collage Station, Texas, USA). An independent-sample t test was used to analyze the differential IGF2BP2 expression between the two groups, and one-way analysis of variance was used for comparing several groups. Log-rank tests were used to assess the prognostic value of IGF2BP2 expression. All the tests were two-sided and were considered statistically significant when the p values were less than 0.05.
Results
IGF2BP2 is overexpressed in human AML
To investigate the differences in IGF2BP2 expression between patients with AML and healthy controls, we analyzed the mRNA levels of IGF2BP2 in two separate patient cohort datasets (GSE7186 and GSE48558); IGF2BP2 expression was higher in AML patients than in healthy controls, especially in the GSE48558 dataset (0.87±0.05 vs 3.1±0.3; a nearly 8-fold (Fig. 1A-B ). Further analysis of the GSE13159 dataset, which contains 542 AML patients and 73 healthy controls, also showed that IGF2BP2 was overexpressed in AML patients (Fig. 1C) . To verify this result in fresh human samples, we prepared primary cells from a cohort of ten primary AML patients and ten healthy volunteers. The clinical characteristics of these patients are shown in Table 1 . There were six male and four female patients, and the histopathologic subtypes of the patients included one M1, two M2, three M4, three M5 and one CML-BC/M. The percentage of primary cells isolated from AML patients ranged from 86% to 95%. We then performed qRT-PCR and western blotting to determine the expression of IGF2BP2 both in AML patients and healthy controls. Since the number of cells isolated from AML patients varied greatly, we did not have sufficient material to perform a western blot analysis for all samples. Therefore, we simply chose the samples with enough cells to perform the Western blots. Furthermore, we performed RT-qPCR analysis instead of a western blot on the samples that did not have enough cells. The results showed that IGF2BP2 was significantly upregulated both at the mRNA and protein levels in the AML patients ( Fig. 1D-E) . Next, we asked whether the increased IGF2BP2 expression was associated with its gene amplification. According to the TCGA datasets (http://www.cbioportal.org/), we found that only 1 in 187 AML patients had IGF2BP2 gene amplification, and 3 had IGF2BP2 gene deletion. In addition, we also analyzed the mutation status of IGF2BP2 in these AML patients, and no IGF2BP2 The results showed that the expression of IGF2BP1 did not differ significantly in these two populations in the three independent datasets (GSE7186, GSE48558 and GSE13159) ( Fig.  2A) . The expression of IGF2BP3 in the AML patients and healthy controls was still controversial. The expression of IGF2BP3 was higher in the AML patients than in the healthy controls (GSE7186), while there was no difference in the other two datasets (GSE48558 and GSE13159) (Fig. 2B) . Taken together, IGF2BP2 rather than IGF2BP1 and IGF2BP3 is overexpressed in human AML.
Association of IGF2BP2 expression with the clinical characteristics of AML patients
To determine the relationship between IGF2BP2 expression and the clinical characteristics of AML patients, we investigated the relevant clinical data in a published dataset (GSE6891) containing 521 AML patients [13, 14] . As shown in Table 2 , IGF2BP2 expression was not associated with sex, age or mutations, such as IDH2, FLT3-TKD, N-ras, K-ras and Evil (p>0.05). However, IGF2BP2 expression was negatively correlated with the CEBPA mutation status (mean value 287 for mutant vs 443 for wild type, RR=0.648, p=0.0001), which is an indicator of good prognosis (Fig. 3A) . In addition, IGF2BP2 expression was positively associated with poor prognostic factors, such as the FLT3-ITD mutation (mean value 490 for mutant vs 409 for wild type, RR=1.198, p=0.0009) (Fig. 3B ) and IDH1 mutation (mean value 570 for mutant vs 421 for wild type, RR=1.354, p=0.0003) (Fig. 3C) (Fig. 3D) . These results indicated that IGF2BP2 expression may be associated with worse clinical characteristics in AML patients.
IGF2BP2 expression correlates with the overall survival of AML patients
Given the relationship between IGF2BP2 expression and prognostic factors, including the CEBPA, FLT3-ITD, and IDH1 mutation statuses and intermediate and poor cytogenetic risk, we next examined the prognostic significance of IGF2BP2 in patients with AML. We compared the overall survival (OS) of 173 AML patients with differential IGF2BP2 expression from the GSE10358 dataset [15] . The results showed that the IGF2BP2 overexpression group (Fig. 4B ) [16] . Therefore, the correlation of IGF2BP2 expression with OS was inconclusive and controversial in different studies. To identify the prognostic value of IGF2BP2, we performed a systematic meta-analysis of eight studies consisting of 1731 patients. The pooled HR value for OS was 1.31 (95% CI: 1.16-1.49; Z = 4.27; p = 0.000) (Fig. 4C ) without heterogeneity (I 2 =33.2% p = 0.163). This result indicated that the HR of overall death was 1.31-fold higher in AML patients with increased IGF2BP2 expression. In addition, both Egger's test (p=0.497) and Begg's test (p=0.458) suggested that no publication bias existed (Fig. 4D) . Taken together, these data indicate that IGF2BP2 overexpression is significantly associated with poor OS in AML patients.
Genetic knockdown of IGF2BP2 represses the growth of AML cell lines
To investigate the role of IGF2BP2 in AML, we searched the GEO database and found a gene expression profile dataset, GSE80946, in which IGF2BP2 was knocked down in a leukemia cell line (Fig. 5A) . We downloaded the original data and performed a GO functional annotation analysis. The results showed that the changed genes were mainly enriched in cell growth and survival (Fig. 5B) . The results of the Gene Set Enrichment Analysis (GSEA) also revealed a significant relation with proliferation (Fig. 5C ). Thus, we transfected the cell lines KG-1a and Kasumi with an IGF2BP2 shRNA lentivirus and performed a proliferation assay. IGF2BP2 expression was verified by an immunoblotting assay. The results showed that IGF2BP2 shRNA caused obvious IGF2BP2 knockdown in the KG-1a and Kasumi cell lines. The proliferation assay showed that IGF2BP2 knockdown significantly inhibited the growth of the AML cell lines KG-1a and Kasumi (Fig. 5D-E) . These results show that the knockdown of IGF2BP2 reduces cell growth in AML cell lines. It had been reported that IGF2BP2 can drive cancer cell proliferation by binding and stabilizing HMGA1 in various solid tumors [17] . We analyzed the relationship between IGF2BP2 and HMGA1 in AML using RNA-sequencing data. The result showed that the knockdown of IGF2BP2 did not significantly alter the expression of HMGA1 (p>0.05). In addition, we performed a co-expression analysis of a dataset that included 542 AML patients (GSE13159) and found that IGF2BP2 was not correlated with the expression of HMGA1 (R=0.005, p=0.89) (Fig. 5F ). The mechanism of IGF2BP2 in maintaining AML proliferation still requires further investigation.
Discussion
IGF2BP2, a member of the conserved family of RNA-binding proteins, forms a complex termed the ribonucleoprotein complex and controls mRNA translation and transport [18] [19] [20] . IGF2BP2 has also been suggested to be upregulated in many solid cancers, and it plays an important role in promoting the growth, migration and metastasis of cancer [9, 10, [21] [22] [23] [24] . However, the role of IGF2BP2 in AML has not been investigated systematically. In this study, we analyzed the differences in IGF2BP2 expression between AML patients and healthy controls by in silico analysis and demonstrated that IGF2BP2 is upregulated in AML patients; furthermore, IGF2BP2 expression was significantly correlated with worse prognosis in AML.
Previous studies have suggested that IGF2BP2 is upregulated in liposarcomas, endometrial adenocarcinomas and breast cancer [21] [22] [23] . A study had also reported that IGF2BP2 in acute lymphoblastic leukemia (ALL) is higher than in healthy donor bone marrow and peripheral blood, while IGF2BP1 and IGF2BP3 is downregulated in ALL [25] . More importantly, IGF2BP2 can serve as a prognostic indicator in several types of solid tumors, including esophageal adenocarcinoma, esophageal squamous carcinoma and glioblastoma [10, 24] . Consistent with these data, we found that IGF2BP2 is overexpressed in primary AML patients and patient cohort datasets. In addition, IGF2BP2 overexpression [26, 27] . AML patients with FLT3-ITD mutations have worse diseasefree and overall survivals [28] . IDH1 is also a frequent mutation in AML patients and confers an adverse prognosis in cytogenetically normal AML patients with the NPM1 mutation but without the FLT3-ITD mutation [29] . Biallelic CEBPA gene mutations represent a distinct molecular entity of cytogenetically normal AML patients, and patients with biallelic CEBPA gene mutations have better overall survival [30] . In this study, we demonstrated that IGF2BP2 was highly expressed in patients with FLT3-ITD and IDH1 mutations and was downregulated in patients with the CEBPA mutation. These results indicated that IGF2BP2 was associated with worse clinical characteristics in AML patients. Second, we performed a meta-analysis to investigate the prognostic significance of IGF2BP2 in AML for the first time. The pooled HR value for OS was 1.31 (95% CI: 1.16-1.49; Z = 4.27; p = 0.00), which indicated that IGF2BP2 overexpression was significantly associated with poor OS in AML patients. In addition, both Egger's test and Begg's test suggested that no publication bias existed in this meta-analysis. Given the connection between high IGF2BP2 expression and AML prognosis, we then tested the role of IGF2BP2 in AML cell lines. Based on the GO and KEGG analyses of more than 60 esophageal adenocarcinoma patients, it has been reported that IGF2BP2 is significantly associated with proliferation and growth [10] . In addition, a recent study reported that the knockdown of IGF2BP2 expression in colorectal cancer cells suppressed cell growth [31] . Our results also showed that the knockdown of IGF2BP2 expression in AML cell lines obviously repressed cell growth. The mechanism of IGF2BP2 in maintaining AML proliferation still requires further investigation. More importantly, it has been suggested that IGF2BP2 -/-mice exhibit greater uncoupled oxygen consumption and a longer lifespan than wild-type mice. These results indicate that the lack of IGF2BP2 has no significant effect on normal cells. Therefore, IGF2BP2 may be a promising therapeutic target in AML.
Conclusion
In summary, our study results indicate that IGF2BP2 expression is upregulated in AML patients. Notably, IGF2BP2 overexpression is associated with worse clinical characteristics in AML patients (CEBPA, FLT3-ITD, and IDH1 mutation statuses as well as intermediate and poor cytogenetic risk) and is significantly associated with the poor overall survival of AML patients. In addition, the genetic knockdown of IGF2BP2 represses the growth of AML cell lines. Thus, IGF2BP2 may serve as a biomarker to predict the prognosis of AML and as a potential therapeutic target in AML patients.
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